Randomized Trial of Thymoglobulin Versus Alemtuzumab (with Lower Dose Maintenance Immunosuppression) Versus Daclizumab in Living Donor Renal Transplantation

Ciancio, Gaetano; Gaynor, Jeffrey J.; Roth, David; Kupin, Warren; Hanson, Lois; Tueros, Lissett; Zarak, Alberto; Ruiz, Phillip; Burke, George W.

doi:10.1016/j.transproceed.2010.08.045

Cited by 38 publications

(32 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…After a 15-month follow-up, there were similar rates of acute rejection and other adverse events in the 3 groups, and 80% of the alemtuzumab patients remained steroid-free. After 36 months, once more there were similar rates of acute rejection and other adverse events [21] .…”

Section: Discussionmentioning

confidence: 80%

“…In the first randomized, prospective trial evaluating alemtuzumab, efficacy appeared similar to induction with either thymoglobulin or daclizumab; of interest, most of the patients in the alemtuzumab arm remained steroid-free [20] . Ciancio et al [21] carried out a parallel, open-label, randomized controlled trial comparing the following three regimens: alemtuzumab, rATG, and daclizumab induction in patients who received deceased donor renal grafts. After a 15-month follow-up, there were similar rates of acute rejection and other adverse events in the 3 groups, and 80% of the alemtuzumab patients remained steroid-free.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Poor Outcomes in Elderly Kidney Transplant Recipients Receiving Alemtuzumab Induction

et al. 2011

View full text Add to dashboard Cite

justing for baseline differences, induction with alemtuzumab was associated with an increased risk of graft loss and death, with an adjusted hazard ratio (AHR) of 1.26 (95% CI 1.08-1.48). Risk was also present at other age cutoffs [age 1 60 (AHR 1.16; 95% CI 1.03-1.31; p = 0.014), age 1 70 (AHR 1.43; 95% CI 1.13-1.81; p = 0.003) and age 1 75 (AHR 1.68; 95% CI 1.07-2.63; p = 0.024)]. Conclusions: In the elderly, alemtuzumab is associated with an escalating risk of death and graft loss in recipients of kidney transplantations.

show abstract

Section: Discussionmentioning

confidence: 80%

Section: Discussionmentioning

confidence: 99%

Poor Outcomes in Elderly Kidney Transplant Recipients Receiving Alemtuzumab Induction

et al. 2011

View full text Add to dashboard Cite

show abstract

“…Most are case reports describing alemtuzumab as salvage or induction therapy. 123,163,[166][167][168][169][170][171][172][173][174][175][176] In a small group of lung transplant recipients with rejection refractory to steroids and ATG, alemtuzumab appeared to be effective in reversing rejection and bronchiolitis obliterans syndrome. 177 Treatment of rejection appears similarly effective in kidney transplant recipients but may be associated with increased early infection-related deaths.…”

Section: Alemtuzumab (Campath)mentioning

confidence: 99%

Antibody-Mediated Rejection in Cardiac Transplantation: Emerging Knowledge in Diagnosis and Management

Colvin¹,

Cook²,

Chang³

et al. 2015

Circulation

283

251

View full text Add to dashboard Cite

“…Schenker et al [77] performed a retrospective study on live donor recipients who had received a single dose of thymoglobulin before transplantation, and demonstrated the beneficial effect thymoglobulin on reducing the BPAR without increasing the incidence of CMV infection. Another comparative study investigated thymoglobulin versus alemtuzumab (Campath-1H) in living donor recipients who showed no difference in the incidence of BPAR, graft survival and patient survival [78]. …”

Section: Role Of Ratg In Live Donor Transplantation (Table 3)mentioning

confidence: 99%

Thymoglobulin and Its Use in Renal Transplantation: A Review

2013

View full text Add to dashboard Cite

Thymoglobulin (Thymoglobulin®; Genzyme, Cambridge, Mass., USA) is a polyclonal antibody which has been used in the field of transplantation over the last four decades. With an initial hesitancy, it is widely used now in the prevention and treatment of rejection following renal transplantation. Thymoglobulin's lack of nephrotoxic properties (unlike calcineurin inhibitors) may potentiate it to be a very useful induction therapy during the early days following transplantation, particularly in a donation after circulatory death programme. More recently its role in conjunction with inhibitors of terminal complement activation has been shown to be beneficial in cross-match-positive transplantation. This review article consolidates up-to-date available evidence to address the therapeutic role of thymoglobulin in immunological tolerance, ischemia perfusion, live donor transplantation, delayed graft function, prevention and treatment of rejection, graft survival and post-transplant lymphoproliferative disorder following renal transplantation.

show abstract

Randomized Trial of Thymoglobulin Versus Alemtuzumab (with Lower Dose Maintenance Immunosuppression) Versus Daclizumab in Living Donor Renal Transplantation

Cited by 38 publications

References 15 publications

Poor Outcomes in Elderly Kidney Transplant Recipients Receiving Alemtuzumab Induction

Poor Outcomes in Elderly Kidney Transplant Recipients Receiving Alemtuzumab Induction

Antibody-Mediated Rejection in Cardiac Transplantation: Emerging Knowledge in Diagnosis and Management

Thymoglobulin and Its Use in Renal Transplantation: A Review

Contact Info

Product

Resources

About